Galveston County Coordinated Community Clinics Governing Board Meeting June 1, 2006 Staff: Kathy Barroso
Willie Toliver Harlan “Mark” Guidry, MD, MPH (ex-officio)
Agenda Upon a motion duly made and seconded, the agenda of June 1, 2006 was unanimously approved. Minutes Upon a motion duly made and seconded, the minutes of April 27, 2006 were unanimously approved. Excused Absences Brian Maxwell and Harvey Bazaman were granted excused absences. Item #1 Executive Report Dr. Guidry presented the Executive report for May 2006. Item #2 Financial Committee Reports
Kathy Barroso, Chief Financial Officer, presented the April 2006 financial report. The budget revisions were also presented and Virginia Valentino made a motion to approve the budget revisions, Dr. Howard seconded, and the motion was carried unanimously. Kathy Barroso also presented the audit engagement letter from Null-Lairson. The board unanimously approved the letter, and Mary McCall, on behalf of Brian Maxwell, will sign it. The new dental fees were presented to the board. Dr. Howard made a motion that the dental fees be approved with an exception that the guidelines be changed. Virginia Valentino seconded, and the motion was carried unanimously. Item #3 Approval of Updated Policies Jay Holland, Chief Operating Officer, presented the policies enclosed in the mail out. Upon a motion made by Dr. Howard and seconded by Dorothy Goodman, the policies were unanimously approved. Item #4 Approval of UTMB OB/GYN Glyburide Research Pam Jahnke, Strategic Plan Evaluator, presented a request from UTMB to enlist 4C’s patients for this research project. Upon a motion made by Dr. Howard and seconded by Virginia Valentino, the approval of the Glyburide research was unanimously approved. Item #5 Evening Clinic Proposal Patrick Butler, 4C’s Business Manager, provided the Board three options for the evening clinics. The Board unanimously approved recommendation #2, which is Monday and Wednesday, one provider to see Pedi only, one provider to see all scheduled patients, and one provider to see walk-ins only. Tuesday and Thursdays will have one provider to see all scheduled patients and one provider to see walk-ins only. Item #6 Privileging and Re-privileging Pam Jahnke, Strategic Plan Evaluator, presented the recommendation from the Dental Director to privilege Barbara Scott, DDS and to re-privilege Michael McRaith, DDS. Upon a motion duly made and seconded, the privileging and re-privileging was unanimously approved. Item #7 Discussion of Pharmacy Services Patrick Butler, 4C’s Business Manager, presented a list of concerns regarding the Pharmacy. This was discussed and Patrick will keep the Board apprised of the situation. Item #8 Access to Care and Customer Service Survey Pam Jahnke, Strategic Plan Evaluator, presented the quarterly access to care measures and the customer service survey. Item #9 Informational Reports The Board received the informational reports as circulated. Item #10 Executive Session – Medical Staffing Proposal The Board entered executive session at 12:55 p.m. The Board ended executive session at 1:03 p.m. Upon entering open session again, Dr. Howard made a motion that the Board approve the executive recommendations to use current salary savings to adjust the budget to increase midlevel pay. Willie Toliver seconded, and the motion was carried unanimously. Executive staff will monitor budgets and services on a monthly basis and keep the Board informed. Only if necessary will staff return to this Board to reconsider allocating reserve dollars. In this case, the Provider will be given a notice of the organization’s intent to evaluate the staff needs for the level of pediatric services provided in the 4C’s clinic and will make a decision within the next year about whether or not it is in the best interest of the 4C’s clinic to continue employing said Provider. Data will be collected and presented to the Board for determination. Adjournment Upon a motion duly made and seconded, the Board adjourned at 1:05 p.m. ____________________________ Brian Maxwell Chairman
∂È̤ÏÂÈ·: ÕÏ. ¶·‡ÏÔ˘1, ¡. √ÈÎÔÓÔÌ¿Î˘2, £. ¶·Ó·Ófi˜3, º. ¶ÂÙ˙ÂÚ›‰Ë4, ™. ¶¤ÙÚÔ‚·5 1Managing Partner BIONOVA, 2Consultant Bio Business Analysis Unit, 3Consultant technology transfer Unit and alernate NCP, 4Pharmacology Consultant 5Science Editor Advanced Cell Technology Completes Acquisition of Mytogen, Inc. lead to a significant
Update on Rosiglitazone Safety Concerns On May 21, 2007, the New England Journal of Medicine published a meta-analysis online that found an increased risk of myocardial infarction (MI) associated with the use of rosiglitazone (odds ratio 1.43; 95% confidence interval [CI], 1.03-1.98; p=0.03).1 Since then, other information has been published, including an interim analysis of data from th